Diabetic Neuropathy Clinical Trial
— ADAPTOfficial title:
Activity for Diabetic Polyneuropathy: the ADAPT Study
The proposed study will randomize participants with diabetic peripheral neuropathy into two groups. One group of participants will receive standard-of-care counseling while the other group will undergo supervised exercise and counseling to increase physical activity.
Status | Recruiting |
Enrollment | 140 |
Est. completion date | April 2022 |
Est. primary completion date | April 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 30 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. T2D defined by ADA criteria. 2. Peripheral neuropathy based on the Toronto Diabetic Neuropathy Expert Group consensus criteria for "Confirmed diabetic sensorimotor peripheral neuropathy". 3. Moderate DPN severity with a UENS of 2-18. 4. Age between 30 and 75. 5. Under the care of an identified Primary Care Physician (PCP). Exclusion Criteria: 1. Any alternative cause for peripheral neuropathy. The following tests must have been found normal within the last 12 months or will be performed pre-randomization: vitamin B12, serum protein electrophoresis and immunofixation. ANA and TSH may be obtained if clinically indicated and not available from clinical records. 2. Family history of a non-diabetic neuropathy in a first-degree relative. 3. Severe or longstanding neuropathy: UENS > 18 or history of foot ulceration or amputation. 4. Participants taking Coumadin or oral factor X or thrombin inhibitor therapy will be considered on an individual basis by the site investigator. 5. Severe edema, dermatologic or lower extremity condition that would increase risk of skin biopsy. 6. A serious medical condition that might shorten life span or prevent exercise. 7. Subjects with obesity or hypertension considered in a dangerous range (BMI> 45, systolic BP >170, or diastolic BP >110) and those who fail a medically supervised graded maximal stress test will be excluded from the study for safety reasons. 8. An inability to understand or cooperate with the procedures of the study 9. Females who are pregnant at screening or actively plan to become pregnant during the study period, because of the marked changes in metabolism anticipated during pregnancy. 10. If ,in the investigators assessment, that participation in the study would be limited by a person's weight, size, or other physical condition. |
Country | Name | City | State |
---|---|---|---|
United States | University of Kansas | Kansas City | Kansas |
United States | University of Utah School of Medicine | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Virginia Commonwealth University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Kansas, University of Utah |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Intraepidermal Nerve Fiber Density (IENFD) | Baseline, 9 months, and 18 months | ||
Primary | Change in Quality of Life (NQOL-DN) Questionnaire Results | Baseline, 9 months, and 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04025320 -
The Effect of Intraneural Facilitation Therapy on Diabetic Patients With Peripheral Neuropathy
|
N/A | |
Completed |
NCT02659007 -
Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga
|
Phase 1 | |
Completed |
NCT01953757 -
A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)
|
N/A | |
Completed |
NCT01707979 -
NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes
|
N/A | |
Completed |
NCT00608439 -
Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00576277 -
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain
|
Phase 1/Phase 2 | |
Completed |
NCT00235443 -
A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT00830011 -
Cognitive Behavioral Therapy for Painful Diabetic Neuropathy
|
N/A | |
Completed |
NCT00931879 -
Lovaza® and Microvascular Function in Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT00190970 -
The Effect of Ruboxistaurin on Small Fiber Function
|
Phase 2 | |
Completed |
NCT00101426 -
Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
|
Phase 3 | |
Completed |
NCT00238550 -
Study of CBME in the Relief of Painful Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT05573685 -
Basket Study (CT-100-002) to Evaluate the Effects of a DiNaMoâ„¢ Component Training
|
N/A | |
Completed |
NCT01822925 -
Study of DA-9801 to Treat Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT01690962 -
A Nutritional Intervention for Diabetic Neuropathy
|
N/A | |
Terminated |
NCT00993018 -
A Study of Effectiveness and Safety of JNJ-42160443 in Patients With Diabetic Painful Neuropathy
|
Phase 2 | |
Withdrawn |
NCT02315235 -
The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy
|
N/A | |
Completed |
NCT00496457 -
Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy
|
Phase 2 | |
Recruiting |
NCT02606747 -
The Balance Control Mechanism of DPN Patients
|
N/A | |
Completed |
NCT02068027 -
Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy
|
Phase 2 |